Pharma Veterans

  WHO Prequalifies First Ever Malaria Treatment for Newborns and Infants – Asrar Qureshi’s Blog Post #1259 Dear Colleagues! This is Asrar Qureshi’s Blog Post #1259 for Pharma Veterans. Pharma Veterans Blogs are published by Asrar Qureshi on its dedicated site https://pharmaveterans.com. Please email to pharmaveterans2017@gmail.com  for publishing your contributions here. Preamble The WHO prequalified Coartem Baby in April 2026 as a malaria treatment designed for infants weighing 2–5 kg (4.4–11 lb). These sweet cherry-flavored, dissolvable tablets treat acute, uncomplicated malaria, addressing a gap in neonatal care. The drug has been developed by Novartis and Medicines for Malaria Venture and is designed for distribution in high-risk areas.  The drug contains artemether and lumefantrine. The combination is not new as such; it has been in use for children and adults for many years. However, the use in newborns and infants was not qualified and relevant dosage forms were no...

World Drug Report 2023 – Part 2 – Asrar Qureshi’s Blog Post #886 Dear Colleagues!  This is Asrar Qureshi’s Blog Post #886 for Pharma Veterans. Pharma Veterans  aims to share knowledge and wisdom from Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi on  WordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here. Credit: Baqir Zaidi Credit: Sinitta Leunen Credit: Towfique Barbhuiya UNODC - United Nations Office on Drugs and Crime has published World Drug Report 2023 (link at the end) which shows where the world is vis-à-vis drugs and crime. I am reproducing here the highlights of the report in summarized way. Key Message #4 – Large inequalities remain in the availability of pharmaceutical opioids for medical consumption, and treatment of drug abuse. The issues with opioid abuse besides, inequality exists even in the availability of these pharmaceutical products between high-in...